1.76
0.56%
-0.01
Handel nachbörslich:
1.75
-0.01
-0.57%
Schlusskurs vom Vortag:
$1.77
Offen:
$1.74
24-Stunden-Volumen:
103.72K
Relative Volume:
0.29
Marktkapitalisierung:
$133.40M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-0.56%
1M Leistung:
-5.88%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
Atyr Pharma Inc Stock (ATYR) Company Profile
Firmenname
Atyr Pharma Inc
Sektor
Branche
Telefon
(858) 731-8389
Adresse
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Atyr Pharma Inc Aktie (ATYR) Neueste Nachrichten
Wall Street SWOT: aTyr Pharma stock rides wave of clinical progress amid risks - Investing.com
Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Rises By 55.5% - Defense World
Atyr PHARMA INC (NASDAQ:ATYR) Short Interest Update - MarketBeat
Comparing ARS Pharmaceuticals (NASDAQ:SPRY) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Aarti Drugs gets 7 observation from USFDA for Tarapur plant - NewsDrum
Actinium Pharmaceuticals (ATNM) vs. Its Rivals Head to Head Comparison - Defense World
A look into Atricure Inc (ATRC)’s deeper side - SETE News
First Light Asset Management LLC Grows Stock Holdings in AtriCure, Inc. (NASDAQ:ATRC) - MarketBeat
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Aarti Drugs shares trade lower after 7 observations from USFDA - Moneycontrol
Buying Buzz: Atyr Pharma Inc [ATYR] Director SCHIMMEL PAUL purchases 52,300 shares of the company - Knox Daily
Balance Sheet Insights: Atyr Pharma Inc (ATYR)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Quest Partners LLC Has $40,000 Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Defense World
Atyr PHARMA (ATYR) versus Its Competitors Critical Survey - Defense World
Aster DM Health, Quality CARE inching closer to a merger deal - The Economic Times
Atyr PHARMA (ATYR) and Its Rivals Head to Head Analysis - Defense World
Atyr PHARMA (NASDAQ:ATYR) versus Exscientia (NASDAQ:EXAI) Critical Survey - Defense World
Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Grows By 27.1% - MarketBeat
Jefferies initates Atyr Pharma Inc (ATYR) rating to a Buy - Knox Daily
ATYR’s 2023 Market Dance: Up 33.33% – Time to Invest? - The InvestChronicle
aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point - Seeking Alpha
Atyr Pharma Inc [ATYR] Records 50-Day SMA of $1.7995 - Knox Daily
Examining Atyr Pharma Inc (ATYR) more closely is necessary - US Post News
Ratios Uncovered: Breaking Down Atyr Pharma Inc (ATYR)’s Trailing Twelve Months Metrics - The Dwinnex
Atyr PHARMA (NASDAQ:ATYR) Coverage Initiated by Analysts at Jefferies Financial Group - Defense World
Jefferies says 'Buy' on aTyr Pharma stock, citing potential breakthrough in pulmonary sarcoidosis - Investing.com Canada
Atyr PHARMA (NASDAQ:ATYR) Now Covered by Jefferies Financial Group - MarketBeat
Jefferies Initiates Coverage of aTyr Pharma (ATYR) with Buy Recommendation - MSN
Critical Comparison: Atyr PHARMA (ATYR) and Its Competitors - Defense World
Is Atyr Pharma Inc (ATYR) positioned for future growth? - SETE News
Critical Comparison: Atyr PHARMA (ATYR) versus Its Peers - Defense World
Analyzing Atyr PHARMA (ATYR) & The Competition - Defense World
Financial Comparison: Atyr PHARMA (ATYR) vs. Its Rivals - Defense World
Atyr PHARMA INC (NASDAQ:ATYR) Short Interest Up 28.2% in August - MarketBeat
aTyr Pharma, Inc. (NASDAQ:ATYR) is largely controlled by institutional shareholders who own 61% of the company - Yahoo Finance UK
aTyr Pharma to Participate in September Investor Conferences - GlobeNewswire
aTyr Pharma to Participate in September Investor Conferences - StockTitan
ATYR (aTyr Pharma) 3-Year EBITDA Growth Rate : 15.30% (As of Jun. 2024) - GuruFocus.com
aTyr Pharma (FRA:471A) Peter Lynch Fair Value : €-21.05 (As of Aug. 20, 2024) - GuruFocus.com
Atyr Pharma Inc (ATYR) rating downgrades by Oppenheimer - Knoxdaily.com
Atyr Pharma Inc (ATYR)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Investor’s Delight: Atyr Pharma Inc (ATYR) Closes Weak at 1.91, Down -4.50 - The Dwinnex
aTyr Pharma (STU:471A) Inventory-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com
ATYR (aTyr Pharma) Volatility : 53.54% (As of Aug. 19, 2024) - GuruFocus.com
aTyr Pharma (FRA:471A) Total Inventories : €0.00 Mil (As of Jun. 2024) - GuruFocus.com
aTyr Pharma (STU:471A) Enterprise Value : €73.04 Mil (As of Aug. 18, 2024) - GuruFocus.com
aTyr Pharma (FRA:471A) Float Percentage Of Total Shares Out - GuruFocus.com
aTyr Pharma (FRA:471A) Peter Lynch Fair Value : €-21.05 (As of Aug. 17, 2024) - GuruFocus.com
ATYR (aTyr Pharma) Short-Term Debt & Capital Lease Obligati - GuruFocus.com
Atyr PHARMA (NASDAQ:ATYR) Rating Reiterated by HC Wainwright - Defense World
Atyr PHARMA INC (NASDAQ:ATYR) to Post Q3 2024 Earnings of ($0.22) Per Share, HC Wainwright Forecasts - Defense World
Finanzdaten der Atyr Pharma Inc-Aktie (ATYR)
Es liegen keine Finanzdaten für Atyr Pharma Inc (ATYR) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):